AOD9604
Also Known As: AOD 9604, AOD-9604, Tyr-hGH 177-191, hGH fragment 177-191, HGH fragment 177-191, Anti-obesity drug 9604, Advanced obesity drug, AOD9604 peptide, Metabol, C-terminal growth hormone fragment, GH fat-loss fragment, lipolytic GH peptide, lipolysis, obesity, anti-obesity, fragment 177-191
AOD9604 is a research-grade Modified C-terminal growth-hormone fragment targeting Lipolysis via beta-3 adrenergic and lipase pathways studied in Weight Loss & Metabolism research. It is supplied strictly for in vitro laboratory research use only - not for human or animal consumption, and not FDA-approved.
Evidence Tier: Research Compound - No approved human use; sold for laboratory research only.
A growth-hormone fragment for fat loss that failed its key human trial; banned in sport.
At A Glance
| Category | Weight Loss & Metabolism |
|---|---|
| Compound Class | Modified C-terminal growth-hormone fragment (hGH 177-191) |
| Molecular Target | Lipolysis via beta-3 adrenergic and lipase pathways; no GH receptor binding; no IGF-1 elevation |
| Molecular Weight | 1815.1 Da |
| Amino Acid Sequence | GH 176-191 with N-terminal Tyr (16 aa) |
| CAS Number | 221231-10-3 |
| Half-Life | ~3 minutes |
| WADA Status | prohibited |
| Evidence Tier | Research Compound |
Mechanism Of Action
It attaches to fat cells and tells them to release stored fat into the blood so it can be burned for energy. At the same time, it stops the body from storing new fat.
Studied For
- Obesity / fat-metabolism research
- Lipolysis / fat burning
- Adipose tissue reduction
- Body fat reduction without IGF-1 elevation
- Visceral fat loss
- Subcutaneous fat reduction
- Weight management
- Metabolic syndrome research
- Fat-loss peptide research
- Non-GH lipid metabolism
- Carbohydrate metabolism
- Anti-obesity research
- Body composition improvement
- Abdominal fat reduction
- Fat oxidation enhancement
- weight loss
- fat burning
- stubborn fat
- cartilage repair
- osteoarthritis
Reported Research Findings
Obese-mouse studies show weight reduction. Important: the pivotal human Phase 2b obesity trial failed its primary endpoint and development was discontinued. Net human weight-loss efficacy is negative.
Safety And Handling Notes
Generally well tolerated in human trials at studied oral doses; long-term and injectable safety uncharacterized.
Failed its pivotal trial; not an approved medicine; a self-affirmed food-additive determination is not FDA drug approval. Named on the WADA 2026 Prohibited List (S2.2.3), prohibited at all times and non-Specified. Research use only.
Regulatory Status
Not FDA-approved (development halted). Named on the WADA 2026 Prohibited List under S2.2.3 (growth hormone fragments, alongside hGH 176-191); prohibited at all times and a non-Specified substance.
Full Reference Detail
Related Research Guides
Maintained By The Pep Nation Lab Research Team. See Our Editorial Standards And Research Methodology For How This Reference Is Sourced And Reviewed.
This Reference Is Provided For In Vitro Laboratory Research Use Only. Not For Human Consumption. See The Full Research Disclaimer.